- Home
- RGCO vs TLSI Comparison
RGCO vs TLSI Comparison
Compare RGCO & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RGCO
- TLSI
- Stock Information
- Founded
- RGCO 1912
- TLSI 2010
- Country
- RGCO United States
- TLSI United States
- Employees
- RGCO N/A
- TLSI N/A
- Industry
- RGCO Oil & Gas Production
- TLSI Medical Specialities
- Sector
- RGCO Utilities
- TLSI Health Care
- Exchange
- RGCO Nasdaq
- TLSI Nasdaq
- Market Cap
- RGCO 209.3M
- TLSI 204.0M
- IPO Year
- RGCO N/A
- TLSI N/A
- Fundamental
- Price
- RGCO $20.34
- TLSI $5.54
- Analyst Decision
- RGCO
- TLSI Strong Buy
- Analyst Count
- RGCO 0
- TLSI 5
- Target Price
- RGCO N/A
- TLSI $10.90
- AVG Volume (30 Days)
- RGCO 12.3K
- TLSI 57.6K
- Earning Date
- RGCO 08-04-2025
- TLSI 08-13-2025
- Dividend Yield
- RGCO 4.08%
- TLSI N/A
- EPS Growth
- RGCO N/A
- TLSI N/A
- EPS
- RGCO 1.29
- TLSI N/A
- Revenue
- RGCO $91,314,087.00
- TLSI $32,141,000.00
- Revenue This Year
- RGCO $10.87
- TLSI $55.52
- Revenue Next Year
- RGCO $3.26
- TLSI $54.76
- P/E Ratio
- RGCO $15.73
- TLSI N/A
- Revenue Growth
- RGCO 9.74
- TLSI 46.20
- 52 Week Low
- RGCO $19.05
- TLSI $3.50
- 52 Week High
- RGCO $24.20
- TLSI $6.08
- Technical
- Relative Strength Index (RSI)
- RGCO 45.32
- TLSI 53.07
- Support Level
- RGCO $20.19
- TLSI $5.18
- Resistance Level
- RGCO $21.61
- TLSI $5.54
- Average True Range (ATR)
- RGCO 0.53
- TLSI 0.32
- MACD
- RGCO 0.00
- TLSI 0.01
- Stochastic Oscillator
- RGCO 12.41
- TLSI 82.81
About RGCO RGC Resources Inc.
RGC Resources Inc is involved in the business of distribution and sale of natural gas to residential, commercial, and industrial customers within its service territory in Roanoke, Virginia, and its surrounding localities. The company also provides certain non-regulated services. The company relies on multiple interstate pipelines to transport natural gas. The company operates in three segments: Gas Utility, which is the key revenue generator; Investment in Affiliates this segment reflects the income generated through the activities of the Company's investment in MVP and Southgate projects and Parent & Other including the unregulated activities of the Company as well as certain corporate eliminations.
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product linesPressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.